DELAHAYE, F., V.H. CHU, J. ALTCLAS, B. BARSIC, A. DELAHAYE, Tomáš FREIBERGER, D.L. GORDON, M.M. HANNAN, B. HOEN, S.S. KANJ, T. LEJKO-ZUPANC, C.A. MESTRES, O. PACHIRAT, P. PAPPAS, C. LAMAS, C. SELTON-SUTY, R. TAN, P. TATTEVIN and A. WANG. One-year outcome following biological or mechanical valve replacement for infective endocarditis. International Journal of Cardiology. Clare (Ireland): Elsevier Ireland Ltd., 2015, vol. 178, January, p. 117-123. ISSN 0167-5273. Available from: https://dx.doi.org/10.1016/j.ijcard.2014.10.125.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name One-year outcome following biological or mechanical valve replacement for infective endocarditis
Authors DELAHAYE, F. (250 France), V.H. CHU (840 United States of America), J. ALTCLAS (32 Argentina), B. BARSIC (191 Croatia), A. DELAHAYE (250 France), Tomáš FREIBERGER (203 Czech Republic, guarantor, belonging to the institution), D.L. GORDON (36 Australia), M.M. HANNAN (372 Ireland), B. HOEN (250 France), S.S. KANJ (422 Lebanon), T. LEJKO-ZUPANC (705 Slovenia), C.A. MESTRES (724 Spain), O. PACHIRAT (764 Thailand), P. PAPPAS (840 United States of America), C. LAMAS (76 Brazil), C. SELTON-SUTY (250 France), R. TAN (36 Australia), P. TATTEVIN (250 France) and A. WANG (840 United States of America).
Edition International Journal of Cardiology, Clare (Ireland), Elsevier Ireland Ltd. 2015, 0167-5273.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30201 Cardiac and Cardiovascular systems
Country of publisher Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 4.638
RIV identification code RIV/00216224:14740/15:00082466
Organization unit Central European Institute of Technology
Doi http://dx.doi.org/10.1016/j.ijcard.2014.10.125
UT WoS 000345697300033
Keywords in English Infective endocarditis; Surgery; Valve prosthesis
Tags rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Eva Špillingová, učo 110713. Changed: 22/3/2016 11:11.
Abstract
Background: Nearly half of patients require cardiac surgery during the acute phase of infective endocarditis (IE). We describe the characteristics of patients according to the type of valve replacement (mechanical or biological), and examine whether the type of prosthesis was associated with in-hospital and 1-year mortality. Methods and results: Among 5591 patients included in the International Collaboration on Endocarditis Prospective Cohort Study, 1467 patients with definite IE were operated on during the active phase and had a biological (37%) or mechanical (63%) valve replacement. Patients who received bioprostheses were older (62 vs 54 years), more often had a history of cancer (9% vs 6%), and had moderate or severe renal disease (9% vs 4%); proportion of health care-associated IE was higher (26% vs 17%); intracardiac abscesses were more frequent (30% vs 23%). In-hospital and 1-year death rates were higher in the bioprosthesis group, 20.5% vs 14.0% (p = 0.0009) and 25.3% vs 16.6% (p < .0001), respectively. In multivariable analysis, mechanical prostheses were less commonly implanted in older patients (odds ratio: 0.64 for every 10 years), and in patients with a history of cancer (0.72), but were more commonly implanted in mitral position (1.60). Bioprosthesis was independently associated with 1-year mortality (hazard ratio: 1.298). Conclusions: Patients with IE who receive a biological valve replacement have significant differences in clinical characteristics compared to patients who receive a mechanical prosthesis. Biological valve replacement is independently associated with a higher in-hospital and 1-year mortality, a result which is possibly related to patient characteristics rather than valve dysfunction. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
PrintDisplayed: 13/7/2024 13:28